hema.to: AI cytometry (original) (raw)
End-to-end AI cytometry solutions
that save time, increase reproducibility and
makes your workflow more flexible.
Seconds from raw cytometry to sound decisions
When hema**.**to is right for you
Your manual gating and reporting is labor-intensive
You dislike variability from human gating
You dislike the lock-in to kits, panels and SOPs
You're held back by rigid on-site workflows, limiting collaboration
Why labs choose hema**.**to's AI solution
Reproducible
Automated pipelines remove operator variability. Results are consistent, reproducible, and expert-level.
Secure
Privacy-first, GDPR-validated. Data anonymized before leaving the lab. Encrypted, EU-hosted, enterprise-grade security.
Lightning fast
Cuts analysis and reporting time >2×.Urgent cases can be prioritized instantly instead of waiting in the queue.
Flexible
Panel-independent. Cloud-based workflows enable remote access. Teams collaborate in real time—no emailing of more screenshots or shared monitors.
.png){kind=logo}
hema**.**to in figures
>4k
analyses supported by hema.to
>600k
FCS files in our data base
98.6%
mean accuracy in our prospective interventional clinical study
4
peer-reviewed publications
Solutions
hema.to Workflow Studio
Your cytometry workflow solution, AI-driven population classification and reporting
hema.to B-NHL
hema.to B-NHL (CE-IVD) offers diagnostic support for patients with B-NHL.
Solutions
hema.to Workflow Studio
Your cytometry workflow solution, AI-driven population classification and reporting
hema.to B-NHL
hema.to B-NHL (CE-IVD) is an add-module and offers diagnostic support for patients with B-NHL.
I am very excited about implementing the decision support system developed by hema.to into the flow cytometry lab space! It will help streamline and automate analyses workflows leading to improved accuracy and turn-around-times.
Prof. Dr. Pozdnyakova
Director of hematopathology at UPenn Medicine
In the long run, there will be only three specialized hematology labs in the Netherlands — I think that hema.to will help us to be amongst them.
Dr. Jürgen Riedl
Hematologist & Co-founder of Result Laboratorium
I really believe in what hema.to is doing. AI truly has the potential to help with many of our challenges in clinical flow cytometry including training new staff, not missing small pathologies or double pathologies, and taking better advantage of the large data sets we produce on any given sample for new diagnostic or predictive information.
Elizabeth Eshel
Coordinator of clinical cytometry at Ziv Medical Center (Israel)
The unique A.I.-based approach developed by hema.to has a transformative potential in cytometry, filling a high unmet need for this method that provides key health and biological metrics in many indications. We are proud and thrilled to join’s team in this endeavor.
Dr. David Sourdive
Co-founder, Executive Vice President
for Strategic Initiatives and Director of Cellectis